艾美疫苗(06660.HK) 公布,旗下全资子公司艾美荣誉(宁波)生物制药已于近日,取得生产无血清迭代狂犬疫苗的药品生产许可证,并将提交药品上市注册。公告指,全球市场目前尚未有无血清狂犬疫苗获批上市,该产品有望成为首个上市产品。
据介绍,艾美疫苗研发的无血清迭代狂犬疫苗是一款迭代升级的产品。疫苗产品中的动物血清残留是导致疫苗接种人群产生过敏等不良反应的重要因素之一,该集团研发的无血清迭代狂犬疫苗,不含有动物血清,显著提高安全性,降低不良反应的发生概率。(js/w)
(港股报价延迟最少十五分钟。沽空资料截至 2025-03-11 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.